Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02796300 · ClinicalTrials.gov registry record · NA
Study to Compare Palindrome vs. BioFlo DuraMax Dialysis Catheters
A NA study, sponsored by University of California, Los Angeles.
- Terminated
- Registry status
- NA
- Development phase
- 32
- Enrollment target
NCT02796300 is a NA study that was terminated before completion, run by University of California, Los Angeles. The registered enrollment target is 32 participants.
The verdict
NCT02796300, a NA study, was terminated before completion, sponsored by University of California, Los Angeles.
- TERMINATED
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
Study Summary
Numerous catheter designs have been studied to increase efficacy and minimize complications of catheter hemodialysis. Major complications of catheters include thrombosis, central venous stenosis, infection, and dialysis inadequacy. Thrombosis must be avoided if possible because using too many catheters may exhaust all of the catheter insertion sites on the body, as well as increase the risk of infection. This prospective study compares the complications and general outcomes of patients who receive hemodialysis using the mainstream Palindrome catheter versus the newer BioFlo DuraMax catheter. This study will examine outcomes of patients who receive hemodialysis using either the Palindrome catheter or the BioFlo catheter. Patients will be observed and outcomes will be recorded for three to six months. Outcomes will be analyzed and compared to draw conclusions on which catheter produces less catheter thrombosis.
Interventions
- DEVICE Bioflo Dialysis Catheter
- DEVICE Palindrome Dialysis Catheter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2017-01-20 |
| Est. Completion | 2019-06-25 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02796300
The ClinicalTrials.gov registry entry for NCT02796300 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bioflo Dialysis Catheter is the first listed.
NCT02796300 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02796300 about?
NCT02796300 is a clinical study titled "Study to Compare Palindrome vs. BioFlo DuraMax Dialysis Catheters". Numerous catheter designs have been studied to increase efficacy and minimize complications of catheter hemodialysis. Major complications of catheters include thrombosis, central venous stenosis, infection, and dialysis inadequacy. Thrombosis must be avoided if possible because using too many cathet...
What is the current status of trial NCT02796300?
This trial is currently terminated. It is a NA study. The enrollment target is 32 participants. The study started on 2017-01-20. Estimated completion is 2019-06-25.
What interventions are being tested in trial NCT02796300?
The interventions under investigation include: Bioflo Dialysis Catheter (DEVICE), Palindrome Dialysis Catheter (DEVICE).
Who is sponsoring clinical trial NCT02796300?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.